Literature DB >> 1309265

Reciprocal antagonism of steroid hormones and BZLF1 in switch between Epstein-Barr virus latent and productive cycle gene expression.

A J Sinclair1, M Brimmell, P J Farrell.   

Abstract

BZLF1 repression of transcription from the Epstein-Barr virus BC-R2 promoter (Cp) was shown to require a glucocorticoid response element in cis and glucocorticoids in trans. The mechanism of the repression is indirect and involves up regulation of the cellular c-fos proto-oncogene. Glucocorticoids maintain Epstein-Barr virus latency, and removal of glucocorticoids from the cell culture medium results in activation of the productive cycle. This inverse regulation of the expression of latent and productive cycle genes contributes to the switch between virus latency and the productive cycle. Glucocorticoid control of BC-R2 might also provide a mechanism for EBNA promoter switching during early infection and in development of the restricted latent pattern of gene expression.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1309265      PMCID: PMC238261     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  47 in total

1.  A promoter of Epstein-Barr virus that can function during latent infection can be transactivated by EBNA-1, a viral protein required for viral DNA replication during latent infection.

Authors:  B Sugden; N Warren
Journal:  J Virol       Date:  1989-06       Impact factor: 5.103

2.  The spliced BZLF1 gene of Epstein-Barr virus (EBV) transactivates an early EBV promoter and induces the virus productive cycle.

Authors:  C M Rooney; D T Rowe; T Ragot; P J Farrell
Journal:  J Virol       Date:  1989-07       Impact factor: 5.103

3.  Nucleotide sequences of mRNAs encoding Epstein-Barr virus nuclear proteins: a probable transcriptional initiation site.

Authors:  J Sample; M Hummel; D Braun; M Birkenbach; E Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

4.  A new technique for the assay of infectivity of human adenovirus 5 DNA.

Authors:  F L Graham; A J van der Eb
Journal:  Virology       Date:  1973-04       Impact factor: 3.616

5.  DNA sequence and expression of the B95-8 Epstein-Barr virus genome.

Authors:  R Baer; A T Bankier; M D Biggin; P L Deininger; P J Farrell; T J Gibson; G Hatfull; G S Hudson; S C Satchwell; C Séguin
Journal:  Nature       Date:  1984 Jul 19-25       Impact factor: 49.962

6.  Mutually exclusive use of viral promoters in Epstein-Barr virus latently infected lymphocytes.

Authors:  M Woisetschlaeger; J L Strominger; S H Speck
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

7.  Epstein-Barr virus nuclear antigen 2 transactivates latent membrane protein LMP1.

Authors:  F Wang; S F Tsang; M G Kurilla; J I Cohen; E Kieff
Journal:  J Virol       Date:  1990-07       Impact factor: 5.103

8.  Induction of Epstein-Barr virus early antigens by corticosteroids: inhibition by TPA and retinoic acid.

Authors:  G Bauer
Journal:  Int J Cancer       Date:  1983-03-15       Impact factor: 7.396

9.  Steroids inhibit tumor promoting agent induced Epstein-Barr virus early antigens in Raji cells.

Authors:  S K Sundar; D V Ablashi; G R Armstrong; M Zipkin; A Faggioni; P H Levine
Journal:  Int J Cancer       Date:  1981-10-15       Impact factor: 7.396

10.  Glucocorticoid induction of the rat tryptophan oxygenase gene is mediated by two widely separated glucocorticoid-responsive elements.

Authors:  U Danesch; B Gloss; W Schmid; G Schütz; R Schüle; R Renkawitz
Journal:  EMBO J       Date:  1987-03       Impact factor: 11.598

View more
  11 in total

1.  Upregulation of tyrosine kinase TKT by the Epstein-Barr virus transactivator Zta.

Authors:  J Lu; S Y Chen; H H Chua; Y S Liu; Y T Huang; Y Chang; J Y Chen; T S Sheen; C H Tsai
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

2.  The Epstein-Barr virus (EBV) nuclear antigen 1 BamHI F promoter is activated on entry of EBV-transformed B cells into the lytic cycle.

Authors:  A L Lear; M Rowe; M G Kurilla; S Lee; S Henderson; E Kieff; A B Rickinson
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

3.  Molecular genetic analysis of Epstein-Barr virus Cp promoter function.

Authors:  T J Evans; P J Farrell; S Swaminathan
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

4.  Linear epitopes of the replication-activator protein of Epstein-Barr virus recognised by specific serum IgG in nasopharyngeal carcinoma.

Authors:  H M Cheng; Y T Foong; A J AbuSamah; J Dillner; C K Sam; U Prasad
Journal:  Cancer Immunol Immunother       Date:  1995-04       Impact factor: 6.968

5.  Identification of cellular target genes of the Epstein-Barr virus transactivator Zta: activation of transforming growth factor beta igh3 (TGF-beta igh3) and TGF-beta 1.

Authors:  C Cayrol; E K Flemington
Journal:  J Virol       Date:  1995-07       Impact factor: 5.103

6.  Reciprocal regulation of the Epstein-Barr virus BamHI-F promoter by EBNA-1 and an E2F transcription factor.

Authors:  N S Sung; J Wilson; M Davenport; N D Sista; J S Pagano
Journal:  Mol Cell Biol       Date:  1994-11       Impact factor: 4.272

7.  Transcriptional activation signals found in the Epstein-Barr virus (EBV) latency C promoter are conserved in the latency C promoter sequences from baboon and Rhesus monkey EBV-like lymphocryptoviruses (cercopithicine herpesviruses 12 and 15).

Authors:  E M Fuentes-Pananá; S Swaminathan; P D Ling
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

8.  Transcription start sites downstream of the Epstein-Barr virus (EBV) Fp promoter in early-passage Burkitt lymphoma cells define a fourth promoter for expression of the EBV EBNA-1 protein.

Authors:  C Nonkwelo; J Skinner; A Bell; A Rickinson; J Sample
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

9.  Partial elimination of Epstein-Barr virus plasmids from Burkitt's lymphoma cells by transfecting the BZLF1 gene.

Authors:  K Takada; Z Ji; S Fujiwara; N Shimizu; A Tanabe-Tochikura
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

10.  Retinoic acid is a negative regulator of the Epstein-Barr virus protein (BZLF1) that mediates disruption of latent infection.

Authors:  N D Sista; J S Pagano; W Liao; S Kenney
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.